BTAI 13F position history: Howard Marks - Oaktree Capital Management
BioXcel Therapeutics, Inc, as reported in Howard Marks - Oaktree Capital Management’s quarterly 13F filings. See all fund managers holding BTAI.
| Quarter | Activity | Shares | Value | % of portfolio | Reported price | |
|---|---|---|---|---|---|---|
| Q2 2026 | Added | 1,380,248 | $1,946,150 | 0.05% | $1.41 | Filing |
| Q1 2026 | No change | 241,188 | $323,193 | 0.01% | $1.34 | Filing |
| Q4 2025 | No change | 241,188 | $385,902 | 0.01% | $1.60 | Filing |
| Q3 2025 | No change | 241,188 | $617,443 | 0.01% | $2.56 | Filing |
| Q2 2025 | New | 241,188 | $436,551 | 0.01% | $1.81 | Filing |